Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
Osimertinib and dacomitinib are approved as first-line treatment of EGFR-mutant NSCLC but resistance can arise. Here, the authors use a computational model to identify an optimal dosing schedule for osimertinib and dacomitinib combination therapy that was confirmed tolerable and effective in an ongo...
Full description
Bibliographic Details
Main Authors: |
Kamrine E. Poels,
Adam J. Schoenfeld,
Alex Makhnin,
Yosef Tobi,
Yuli Wang,
Heidie Frisco-Cabanos,
Shaon Chakrabarti,
Manli Shi,
Chelsi Napoli,
Thomas O. McDonald,
Weiwei Tan,
Aaron Hata,
Scott L. Weinrich,
Helena A. Yu,
Franziska Michor |
Format: | Article
|
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Nature Communications
|
Online Access: | https://doi.org/10.1038/s41467-021-23912-4
|